Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Pharvaris | 2026 | Post-IPO Equity | Undisclosed | Zug |
| Tempest Therapeutics | 2026 | Post-IPO Equity | Undisclosed | San Francisco |
| Relay Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Cambridge |
| Cerevance | 2026 | Series C | $47.0M | Boston |
| GH Research | 2026 | Post-IPO Equity | Undisclosed | Dublin |
| ImageneBio | 2026 | Post-IPO Equity | Undisclosed | San Diego |
| Solid Biosciences | 2026 | Post Ipo Equity | $240.0M | Charlestown |
| Seaport Therapeutics | 2026 | Grant | $15.0M | Boston |
| Indomo | 2025 | Seed | $25.0M | San Francisco |
| Thyme Care | 2025 | Series D | $97.0M | Nashville |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Pharvaris | Post-IPO Equity | Undisclosed | Zug, Switzerland |
| 2 | Tempest Therapeutics | Post-IPO Equity | Undisclosed | San Francisco, United States |
| 3 | Relay Therapeutics | Post-IPO Equity | Undisclosed | Cambridge, United States |
| 4 | Cerevance | Series C | $47.0M | Boston, United States |
| 5 | GH Research | Post-IPO Equity | Undisclosed | Dublin, Ireland |
| 6 | ImageneBio | Post-IPO Equity | Undisclosed | San Diego, United States |
| 7 | Solid Biosciences | Post Ipo Equity | $240.0M | Charlestown, United States |
| 8 | Seaport Therapeutics | Grant | $15.0M | Boston, United States |
| 9 | Indomo | Seed | $25.0M | San Francisco, United States |
| 10 | Thyme Care | Series D | $97.0M | Nashville, United States |
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
ImageneBio is dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.
Indomo is a clinical-stage firm that aims to improve access to quality healthcare through novel device-enabled treatments.
Thyme Care is a healthcare company that provides oncology care management services.
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health.
RayThera is dedicated to developing small molecule therapies specifically targeting unmet needs in immunology.
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
Pleno is a biotechnology company that aims speeding up disease diagnosis and treatment.
Sollis Health offers concierge medical centers that provide on-demand care for families, including same-day visits and virtual care options.
Foresight Diagnostics develops novel technology for detect cancers from a simple blood draw.
Spear Bio is a biotech company that focuses on the detection of ultrasensitive protein.
Evonetix is a provider of a desktop platform designed to synthesize DNA at unprecedented accuracy and scale.
Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
Midi Health provides virtual care for women in midlife, offering clinician support for menopause, hormonal health, and related conditions.
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Foresite Capital has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Foresite Capital's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Biopharma. The firm invests across 18 different industry categories.
Among tracked funding rounds, Vaxcyte received $632.5M in a Post Ipo Equity round. Foresite Capital's total known invested capital is $8.3B.
Foresite Capital's average investment size is $127.9M across its portfolio of 81 companies.
Recent Foresite Capital portfolio additions include Pharvaris, Tempest Therapeutics, Relay Therapeutics, Cerevance, GH Research. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors